The fundamental bottleneck in nanomedicine is not payload capacity, but navigation. When purely synthetic nanoparticles are injected into the bloodstream, the host's immune system immediately recognizes them as foreign invaders. The mononuclear phagocyte system (MPS)—primarily macrophages in the liver and spleen—rapidly clears these particles, drastically reducing their therapeutic window.
To bypass this, traditional nanomedicine relies on chemical modifications like PEGylation (coating particles with polyethylene glycol) to create a hydrating layer that delays immune recognition. However, PEGylation is an imperfect shield that can still trigger immune responses over time.
Biomimetic cell membrane camouflage solves this problem by shifting from chemical modification to biological disguise. Instead of synthesizing a synthetic coat, researchers harvest actual lipid bilayers from native cells—such as red blood cells, platelets, macrophages, or cancer cells—and wrap them around synthetic nanoparticle cores. The resulting core-shell structure inherits the exact, evolutionary-refined surface topology of the source cell, allowing it to hide in plain sight and actively navigate complex biological environments.
The Mechanism of Stealth: Hiding in Plain Sight
Why does a cell membrane coat work so much better than a synthetic polymer? The answer lies in the dense forest of signaling proteins embedded within native cell membranes.
A prime example is CD47, a transmembrane protein found abundantly on red blood cells (erythrocytes). CD47 acts as a universal "don't eat me" signal by binding to SIRP$\alpha$ receptors on macrophages, actively inhibiting phagocytosis. When a synthetic nanoparticle is wrapped in an erythrocyte membrane, it displays these native CD47 proteins in their correct biological orientation.
As Chen demonstrates in Intravenous iRGD‐Guided, RBC‐Membrane Camouflaged Lactococcus Lactis Remodels Cold NSCLC and Enhances PD‐1 Blockade, this cloaking strategy is powerful enough to protect not just nanoparticles, but even living engineered bacteria from immune clearance, significantly prolonging their circulation time. Similarly, Ru et al. showed in Synthesis of calcium carbonate nanoparticles in erythrocytes enables efficient removal of extracellular lead ions that utilizing erythrocyte membranes prevents off-target accumulation in organs like the liver and spleen, allowing the internal payload to function safely within the bloodstream.
The Mechanism of Homing: Exploiting Inherent Cellular Affinities
Biomimetic coatings do more than just hide nanoparticles; they also inherit the natural homing and adhesion properties of the source cells. This allows for highly precise targeting without the need to chemically conjugate fragile antibodies to the nanoparticle surface.
Homotypic Targeting
Cancer cells possess an innate ability to bind to one another—a phenomenon known as homotypic adhesion, which drives solid tumor formation and metastasis. This affinity is mediated by specific surface adhesion molecules like cadherins and cell adhesion molecules (CAMs).
When nanoparticles are coated with membranes extracted from a specific cancer cell line, they leverage these exact self-recognition properties to home back to the tumor of origin. Lu et al. leveraged this dual benefit in Antimonene with two-orders-of-magnitude improved stability for high-performance cancer theranostics, demonstrating that a cancer cell membrane shield provides physical protection against premature oxidation while ensuring the particles naturally bind to identical tumor cells. This strategy was further validated by Zhuang et al. in Artificial cell vesicle-mediated delivery of Catharanthus roseus (L.) G. Don-derived vinca alkaloids for enhanced antitumor efficacy, where leukemia cell membranes were used to deliver potent chemotherapy drugs back to identical target cells with high precision.
Pathological Site Targeting
Other cell types are naturally programmed to migrate toward injury or inflammation. Platelets, for example, inherently home to disrupted vascular walls and inflamed tissues.
In Platelet membrane-camouflaged nanoparticles carry microRNA inhibitor against myocardial ischaemia‒reperfusion injury, Wang et al. exploited this mechanism to deliver therapeutic microRNA inhibitors directly to damaged cardiac tissue, bypassing rapid hepatic clearance. Similarly, macrophages naturally cross biological barriers to reach sites of cerebral inflammation. Niu et al. demonstrated in Carbon Monoxide Nanomodulator Reverses Ischemia‐Reperfusion Injury in Stroke: A Novel Dual‐Channel Therapy Mode of Co‐driving Neuroprotection and Neurogenesis that macrophage-derived coatings allow synthetic nanogenerators to successfully traverse the blood-brain barrier and localize within ischemic stroke regions.
Next-Generation Membrane Engineering
The field is rapidly evolving from using simple, single-source cell membranes to advanced, engineered membrane architectures.
To achieve multiple therapeutic goals simultaneously, researchers are developing hybrid membranes by fusing different cell types together. For instance, fusing red blood cell membranes with cancer cell membranes creates a hybrid vesicle that possesses both the long-circulating properties of the erythrocyte and the tumor-homing capabilities of the cancer cell. The authors of Combinational Antitumor Strategies Based on the Active Ingredients of Toad Skin and Toad Venom highlight how these hybrid systems significantly improve the pharmacokinetic profiles and targeting precision of synthetic drug carriers compared to single-membrane systems.
Furthermore, genetic engineering allows researchers to customize the surface protein landscape of the source cells before their membranes are harvested. Xing et al. demonstrated this paradigm in Genetically Engineered Biomimetic Nanovesicles Co-Deliveing a Checkpoint Inhibitor and Doxorubicin for Enhanced Cancer Chemo-Immunotherapy by harvesting membranes from cells genetically modified to overexpress PD-1 receptors. This approach creates a multi-functional nanocarrier that inherently acts as an immune checkpoint inhibitor while carrying a traditional chemotherapy payload inside.
By shifting the engineering focus from synthesizing artificial materials to repurposing nature's own cellular interfaces, biomimetic membrane coating provides an elegant solution to the dual challenges of immune evasion and precise targeting in nanomedicine.
Key Foundational Work
Internalization Characterization of Si Nanorod with Camouflaged Cell Membrane Proteins Reveals ATXN2 as a Negative Regulator (2019) — contributed 3 concept elements to this direction.
Antimonene with two-orders-of-magnitude improved stability for high-performance cancer theranostics (2019) — contributed 2 concept elements to this direction.
Synthesis of calcium carbonate nanoparticles in erythrocytes enables efficient removal of extracellular lead ions (2019) — contributed 2 concept elements to this direction.